In March 2025, vTv Therapeutics announced that the clinical hold placed by the FDA in July 2024 on the cadisegliatin clinical program was lifted on March 14, 2025, following the Company's ...

VTV is a passively managed fund that follows a full-replication strategy. The ETF was established on January 26, 2004. Since April 24, 2024, the fund’s expense ratio has been 0.04%. Its 30-day ...

VOV.VN - Báo điện tử VOV, tin tức thời sự về chính trị, kinh tế, đời sống, xã hội, pháp luật, thể thao, văn hóa, giải trí, ...

vTv Therapeutics expects to resume the trial ... insulin alone after reinitiating the CATT1 Phase 3 trial.” In July 2024, the FDA placed a clinical hold on the cadisegliatin clinical program.

VTV.vn - The Business Law Flow Report 2024, recently released by the Viet Nam Chamber of Commerce and Industry (VCCI), has ...

HIGH POINT, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq ... reported financial results for the fourth quarter and year ended December 31, 2024, and provided an update on ...